As the world population has almost doubled in 50 years, and the average lifespan is increasing, we are facing new diseases, pushing our biotechnology skills ever further and always going beyond the laws of nature.
Today, it is estimated that more than a third of the global pharmaceutical market is in the hands of ten pharmaceutical companies, six of which are based in the United States and four in Europe. Even if English is becoming a lingua franca in the international scientific community, particularly in the research field, it should not be forgotten that many clinical tests are conducted in non-English-speaking countries and that most medicines commercialized in one country are developed or manufactured in another country.